Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Phase 3 trial results Cagrilintide and semaglutide (Novo Nordisk) Long-acting amylin analogue and glucagon-like peptide-1 receptor agonist Treatment of overweight or obesity in patients without type 2 ...

Following after is MET-233i, an ultra-long-acting amylin analogue that will be developed as a monotherapy and in combination with GLP-1-acting drugs, including MET-097i, which is in phase 1.

GLP-1 analogues produce significant weight loss along with an improvement in glycemia. DPP-IV inhibitors are well tolerated, effective and weight neutral. Neither therapy has a proven long-term ...

One of the most important inventions of the twentieth century was broadcasting with analogue radio and television systems. The last few years, however, have seen the birth of digital broadcasting.

This article will also examine some future avenues for development, including gut hormone analogues that promise to combine powerful weight reduction with beneficial effects on glucose metabolism.